Noven Announces Executive Appointments

-- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN), a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, today announced two recent appointments within the company’s management team.

Jeffrey F. Eisenberg, Esq., formerly Noven's Vice President – Strategic Alliances & General Counsel, has been appointed Senior Vice President – Strategic Alliances. In this role, Mr. Eisenberg will be the senior officer in charge of managing the company’s relationships with its strategic partners, including Novartis Pharma AG, Endo Pharmaceuticals Inc., Shire Pharmaceuticals Group plc, P&G Pharmaceuticals and others. Mr. Eisenberg joined Noven as General Counsel in 1998. Prior to Noven, he served as Associate General Counsel, and then as Acting General Counsel, of IVAX Corporation. Prior to IVAX, he was a corporate securities lawyer at Steel Hector & Davis, LLP.

Jeff T. Mihm, Esq., Noven's Assistant General Counsel since 2003, will succeed Mr. Eisenberg as the company's General Counsel, and will supervise all legal matters at the company. Prior to Noven, he served as Senior Corporate Counsel to Panamerican Beverages, Inc., and previously was a partner in the corporate securities department of Steel Hector & Davis, LLP.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is committed to expanding the universe of available transdermal therapies for the benefit of patients, partners and shareholders. See www.noven.com for additional information.

Contact:
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916